Literature DB >> 3732887

Disorganisation of intermediate filament structure in alcoholic and other liver diseases.

C Barbatis, J Morton, J C Woods, J Burns, J Bradley, J O McGee.   

Abstract

The distribution of Mallory body antigens JMB1 and 2 was examined in 82 human fresh diagnostic needle liver biopsies and 28 necropsies by the indirect immunoperoxidase technique using 2 monoclonal antibodies (anti-JMB1 and 2) against Mallory bodies. The JMB1 antigen was detectable in bile duct epithelium and in hepatocytes of histologically normal livers. It was also found in all Mallory bodies in various hepatic disorders. This antigen was markedly increased in the cytoplasm of all liver cells in acute alcoholic hepatitis superimposed on alcoholic cirrhosis, in most cases of acute alcoholic hepatitis, and in severe fatty infiltration of the liver with or without Mallory body formation. Mallory bodies contained this antigen but the cytoplasm of Mallory body containing cells lacked JMB1. In normal liver the JMB2 antigen was localised on the cytoplasmic intermediate filament network of hepatocytes and bile duct epithelium; and almost all Mallory bodies also contained this antigen but the adjacent cytoplasm of these cells lacked JMB2. In severe alcoholic liver disease these antigens could not be detected in large zones of hepatocytes even when these hepatocytes did not contain Mallory bodies. It is evident that there is disorganisation of intermediate filament constituents in severe alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732887      PMCID: PMC1433570          DOI: 10.1136/gut.27.7.765

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  Evidence against interconversion of microtubules and filaments.

Authors:  M DeBrabander; F Aerts; R Van de Veire; M Borgers
Journal:  Nature       Date:  1975-01-10       Impact factor: 49.962

2.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

3.  Lymphocyte transformation and alcoholic liver injury.

Authors:  M F Sorrell; C M Leevy
Journal:  Gastroenterology       Date:  1972-12       Impact factor: 22.682

4.  Natural history of alcoholic hepatitis. 3. Histological changes.

Authors:  J T Galambos
Journal:  Gastroenterology       Date:  1972-12       Impact factor: 22.682

5.  The ultrastructure of Mallory body filaments.

Authors:  K D Wiggers; S W French; B A French; B N Carr
Journal:  Lab Invest       Date:  1973-12       Impact factor: 5.662

Review 6.  5'-Terminal caps, cap-binding proteins and eukaryotic mRNA function.

Authors:  A J Shatkin; E Darzynkiewicz; Y Furuichi; H Kroath; M A Morgan; S M Tahara; M Yamakawa
Journal:  Biochem Soc Symp       Date:  1982

7.  The early stage of liver injury in the alcoholic.

Authors:  H A Edmondson; R L Peters; H H Frankel; S Borowsky
Journal:  Medicine (Baltimore)       Date:  1967-03       Impact factor: 1.889

Review 8.  Alcoholic hepatitis. Cell-mediated immunological response to alcoholic hyalin.

Authors:  R K Zetterman; A Luisada-Opper; C M Leevy
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

9.  Ultrastructure of alcoholic hyalin and fate of the affected hepatocytes.

Authors:  H J Rumpelt
Journal:  Virchows Arch B Cell Pathol       Date:  1977-04-15

10.  Sex-related differences among 100 patients with alcoholic liver disease.

Authors:  M Y Morgan; S Sherlock
Journal:  Br Med J       Date:  1977-04-09
View more
  2 in total

1.  Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat.

Authors:  G Abdel-Aziz; G Lebeau; P Y Rescan; B Clément; M Rissel; Y Deugnier; J P Campion; A Guillouzo
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Changes in the enterocyte cytoskeleton in newborn rats exposed to ethanol in utero.

Authors:  J F Montes; G Estrada; M D López-Tejero; J García-Valero
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.